Twin Capital Management Inc. Sells 8,983 Shares of Cencora, Inc. $COR

Twin Capital Management Inc. lessened its holdings in Cencora, Inc. (NYSE:COR) by 64.9% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 4,860 shares of the company’s stock after selling 8,983 shares during the period. Twin Capital Management Inc.’s holdings in Cencora were worth $1,457,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in COR. Atlantic Edge Private Wealth Management LLC grew its holdings in Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after buying an additional 35 shares in the last quarter. Cornerstone Planning Group LLC boosted its position in shares of Cencora by 106.7% during the first quarter. Cornerstone Planning Group LLC now owns 93 shares of the company’s stock worth $26,000 after acquiring an additional 48 shares during the last quarter. Costello Asset Management INC purchased a new position in Cencora during the first quarter valued at $28,000. University of Texas Texas AM Investment Management Co. purchased a new position in Cencora during the first quarter valued at $39,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in Cencora in the 2nd quarter valued at $61,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Stock Performance

NYSE COR opened at $360.29 on Friday. The business’s 50 day moving average price is $312.89 and its 200-day moving average price is $298.79. Cencora, Inc. has a fifty-two week low of $223.92 and a fifty-two week high of $362.00. The company has a market cap of $69.85 billion, a P/E ratio of 37.07, a P/E/G ratio of 1.56 and a beta of 0.63. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The company had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. During the same period in the previous year, the firm earned $3.34 earnings per share. Cencora’s quarterly revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Sell-side analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date is Friday, November 14th. Cencora’s dividend payout ratio (DPR) is presently 22.63%.

Analysts Set New Price Targets

Several research analysts have commented on COR shares. Evercore ISI set a $400.00 price objective on shares of Cencora and gave the company an “outperform” rating in a report on Thursday. Robert W. Baird increased their price target on Cencora from $355.00 to $395.00 and gave the company an “outperform” rating in a research note on Thursday. Wall Street Zen downgraded Cencora from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Morgan Stanley set a $330.00 target price on Cencora and gave the company an “equal weight” rating in a research report on Wednesday, July 16th. Finally, Mizuho raised their target price on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a report on Thursday. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $348.00.

Insider Buying and Selling

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of the company’s stock in a transaction on Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the transaction, the chief executive officer owned 37,940 shares of the company’s stock, valued at $12,398,792. This represents a 11.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the sale, the chairman owned 305,913 shares in the company, valued at approximately $88,671,942.18. The trade was a 9.30% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 41,544 shares of company stock worth $12,230,941. Insiders own 10.80% of the company’s stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.